Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors

Robert A Smith1*, Geoffrey S Gottlieb2, A Dusty Miller1,3

Abstract

Background: XMRV (xenotropic murine leukemia virus-related virus) is the first known example of an exogenous gammaretrovirus that can infect humans. A limited number of reports suggest that XMRV is intrinsically resistant to many of the antiretroviral drugs used to treat HIV-1 infection, but is sensitive to a small subset of these inhibitors. In the present study, we used a novel marker transfer assay to directly compare the antiviral drug sensitivities of XMRV and HIV-1 under identical conditions in the same host cell type.

Results: We extend the findings of previous studies by showing that, in addition to AZT and tenofovir, XMRV and HIV-1 are equally sensitive to AZddA (3′-azido-2',3'-dideoxyadenosine), AZddG (3′-azido-2',3'-dideoxyguanosine) and adefovir. These results indicate that specific 3′-azido or acyclic nucleoside analog inhibitors of HIV-1 reverse transcriptase (RT) also block XMRV infection with comparable efficacy in vitro. Our data confirm that XMRV is highly resistant to the non-nucleoside RT inhibitors nevirapine and efavirenz and to inhibitors of HIV-1 protease. In addition, we show that the integrase inhibitors raltegravir and elvitegravir are active against XMRV, with EC50 values in the nanomolar range.

Conclusions: Our analysis demonstrates that XMRV exhibits a distinct pattern of nucleoside analog susceptibility that correlates with the structure of the pseudosugar moiety and that XMRV is sensitive to a broader range of antiretroviral drugs than has previously been reported. We suggest that the divergent drug sensitivity profiles of XMRV and HIV-1 are partially explained by specific amino acid differences in their respective protease, RT and integrase sequences. Our data provide a basis for choosing specific antiretroviral drugs for clinical studies in XMRV-infected patients.

Background

The genus gammaretroviridae includes several well-characterized exogenous retroviruses that cause leukemia, lymphoma and other diseases in their natural hosts [1]. Although gammaretroviruses have been isolated from several vertebrate species, until recently, the only evidence that these agents could infect humans was the strong sequence similarity between certain human endogenous retroviruses and gammaretroviruses from other mammalian species [2]. In 2006, Urisman and colleagues reported the discovery of novel gammaretroviral cDNA sequences in tumor samples from patients with prostate cancer [3]. Full-length viral clones derived from the patient tissues were shown to be genetically similar to xenotropic strains of murine leukemia virus (MLV), and thus, the novel retrovirus was named xenotropic MLV-related virus (XMRV).

Subsequent studies have provided compelling evidence that XMRV is indeed the first known example of an exogenous human gammaretrovirus. XMRV sequences have been identified in tumor samples from three additional cohorts of prostate cancer patients [4-6], in a prostate carcinoma cell line [7], and in secretions expressed from cancerous prostate tissues [8]. Virus produced from a full-length XMRV molecular clone can infect primary prostate cells in culture, as well as several immortalized cell lines [7-12], and gammaretrovirus-like particles have been identified in XMRV-infected cultures by electron microscopy [5,7]. Although XMRV lacks direct transforming activity, foci of transformed cells appear at low frequencies in XMRV-infected fibroblast cultures, suggesting that the virus is capable of promoting carcinogenesis via insertional activation of cellular...
oncogenes [13]. Importantly, the chromosomal locations of XMRV proviruses have been mapped in tissue samples from 9 different patients with prostate cancer, confirming that XMRV can integrate into the human genome in vivo [11,14].

Following the discovery of XMRV in prostate tumor tissues, a PCR-based survey identified XMRV DNA in peripheral blood mononuclear cells (PBMC) from 68 of 101 chronic fatigue syndrome (CFS) patients living in the United States, as well as 8 of 218 healthy controls [15]. Remarkably, co-culture experiments revealed the presence of infectious XMRV in activated PBMC and in cell-free plasma samples from PCR-positive CFS patients, suggesting that these individuals harbor significant levels of replication-competent XMRV in the periphery. Although other studies of CFS and prostate cancer patients living outside the United States have failed to detect XMRV [16-20], data showing that the virus can infect human cells in vitro [7-12] and in vivo [11,14] provide a solid rationale for identifying antiviral inhibitors that block XMRV replication.

A growing body of evidence suggests that XMRV is intrinsically resistant to many of the drugs used to treat HIV-1 infection, but is sensitive to a small subset of antiretroviral inhibitors. In an initial analysis of XMRV drug susceptibility, treatment of immortalized prostate cells with 30 nM AZT inhibited XMRV infection by a factor of 25-fold; equivalent concentrations of other antiretroviral drugs had no effect on XMRV infection [21]. A subsequent study in cultured cells found that XMRV and HIV-1 exhibit comparable sensitivities to antiretroviral inhibitors [22]. Finally, Singh et al. reported that AZT, tenofovir disoproxil fumarate (TDF), and raltegravir suggesting that these drugs are relatively potent inhibitors of XMRV replication [22]. Importantly, the chromosomal locations of XMRV from 9 different patients with prostate cancer, confirming that XMRV can integrate into the human genome in vivo [11,14].

Results

Comparison of HIV-1 and XMRV drug susceptibilities

We used a previously-described marker rescue assay [7,25] in conjunction with a Tat-inducible, β-gal-expressing HeLa cell line (MAGIC-5A) [26] to quantify the susceptibility of XMRV to antiretroviral inhibitors. Our XMRV stocks were derived from two independently-isolated strains of the virus: XMRVVP62 and XMRV22Rv1. XMRVVP62 was produced from a full-length molecular clone (pVP62) that was previously constructed by joining two overlapping cDNA fragments amplified from prostate tumor tissues [3,11]. For our experiments, high-titer XMRVVP62 stocks were generated by transfecting pVP62 into LNCaP prostate cancer cells [11]. XMRV22Rv1 was originally discovered in a prostate carcinoma cell line (22Rv1) that had been grown by xenotransplantation in nude mice [7,27]. 22Rv1 cells contain multiple integrated copies of the XMRV genome and release high titers of infectious XMRV into the culture supernatant [7].

To generate viruses for drug susceptibility testing, HTX human fibrosarcoma cells were transduced with an MLV vector encoding HIV-1 tat (LtatSN) and were subsequently infected with either XMRVVP62 or XMRV22Rv1 (Figure 1). The resultant stocks (XMRVVP62 + LtatSN) were mixtures of native XMRV and XMRV-pseudotyped virions [LtatSN(XMRV)] in which LtatSN RNA was packaged together with XMRV Gag, Pol and Env proteins; only the LtatSN(XMRV) fraction was detected in subsequent culture steps. To quantify drug susceptibility, MAGIC-5A cultures were treated with varying concentrations of our drug susceptibility measurements were not influenced by differences in the relative replication rates of HIV-1 and XMRV. As in previous reports, we found that XMRV is intrinsically resistant to nevirapine, efavirenz, foscarinet, and all FDA-approved inhibitors of HIV-1 protease. However, our data also show that in addition to AZT and tenofovir, XMRV and HIV-1 are comparably sensitive to other structurally-related NRTIs. These findings reveal a distinct pattern of NRTI sensitivity in XMRV that correlates with the structure of the pseudo-sugar moiety. We also demonstrate that the integrase inhibitor elvitegravir suppresses XMRV infection with an EC50 similar to that of AZT, whereas raltegravir is the most potent anti-XMRV agent of all the inhibitors tested. These data suggest that the inhibitor-binding surfaces of HIV-1 and XMRV integrase share similar topologies despite numerous differences in their respective amino acid sequences. Collectively, our study reveals important features of the inhibitor specificities of XMRV RT and integrase and expands the number of antiretroviral drugs that are active against XMRV in culture.
NRTIs, NNRTIs, or integrase inhibitors, and infected with XMRVVP62 +LtatSN or XMRV22Rv1 +LtatSN (Figure 1). Entry of XMRV occurs through the interaction of the virus with xenotropic and polytropic retrovirus receptor 1 (XPR1), which is endogenously expressed in HeLa cell lines [28]. XMRV+LtatSN infection of MAGIC-5A cells induced the expression of β-galactosidase (β-gal) via Tat-mediated transactivation of an upstream HIV-1 LTR promoter. β-gal+ (blue) cells are detected by staining the MAGIC-5A monolayers with X-gal (dashed arrows). Entry of XMRV into HTX/LtatSN and MAGIC-5A cells is mediated by the endogenously-expressed xenotropic and polytropic retrovirus receptor 1 (XPR1). For HIV-1, virus stocks were produced by transient transfection (dotted arrow) of 293T/17 cells with pNL4-3. As with XMRV+LtatSN, infection of MAGIC-5A cells with HIV-1NL4-3 (red virions) results in Tat expression and β-gal+ focus formation. MAGIC-5A cells were previously engineered to express the CD4 receptor and CCR5 coreceptor for HIV-1 entry; these cells also express the endogenous CXCR4 coreceptor [26]. Dashed vertical lines indicate the stages at which protease inhibitors (left) and reverse transcriptase or integrase inhibitors (right) were added to the culture supernatants.

**Figure 1 Drug susceptibility assays for XMRV and HIV-1.** For XMRV, HTX/LtatSN cells were infected (solid arrows) with XMRV22Rv1 or XMRVVP62, resulting in the release of native XMRV (gray virions) as well as XMRV-pseudotyped virions that contain LtatSN RNA (LtatSN(XMRV); blue virions). Infection of MAGIC-5A cells with XMRV+LtatSN results in transfer of the HIV-1 tat marker gene, thereby inducing β-gal expression through Tat-dependent transactivation of an upstream HIV-1 LTR promoter. β-gal+ (blue) cells are detected by staining the MAGIC-5A monolayers with X-gal (dashed arrows). Entry of XMRV into HTX/LtatSN and MAGIC-5A cells is mediated by the endogenously-expressed xenotropic and polytropic retrovirus receptor 1 (XPR1). For HIV-1, virus stocks were produced by transient transfection (dotted arrow) of 293T/17 cells with pNL4-3. As with XMRV+LtatSN, infection of MAGIC-5A cells with HIV-1NL4-3 (red virions) results in Tat expression and β-gal+ focus formation. MAGIC-5A cells were previously engineered to express the CD4 receptor and CCR5 coreceptor for HIV-1 entry; these cells also express the endogenous CXCR4 coreceptor [26]. Dashed vertical lines indicate the stages at which protease inhibitors (left) and reverse transcriptase or integrase inhibitors (right) were added to the culture supernatants.

We initially measured the susceptibility of XMRV to each of seven different NRTIs that are FDA-approved for treating HIV-1 infection. AZT showed the most potent anti-XMRV activity of all the nucleoside analogs tested (Table 1); EC50 values for XMRVVP62+LtatSN, XMRV22Rv1+LtatSN and HIV-1NL4-3 were similar for AZT, indicating that these viruses are comparably susceptible to the analog. These results agree with a previous comparison of the AZT sensitivity of HIV-1 and HIV-1NL4-3.
XMRV using a reporter virus-based assay [22]. We also found that, relative to HIV-1NL4-3, XMRVVP62+LtatSN and XMRV22Rv1+LtatSN were fully sensitive to tenofovir (the active form of TDF), as the observed EC50 values were not significantly different between these three viruses (Table 1). In contrast, XMRV was 13-34-fold resistant to ddI, d4T and abacavir relative to HIV-1NL4-3. Higher levels of resistance were observed for 3TC and FTC, which failed to inhibit XMRV infection at doses that were 100-fold greater than the corresponding EC50s for HIV-1NL4-3.

To further characterize the nucleoside analog susceptibility of XMRV, we determined the antiviral activities of additional NRTIs that are active against HIV-1 and other retroviruses, but that are not currently approved for treating HIV-1 infection. AZddA and AZddG contain an azido group at the 3′ position of the ribosyl sugar, and thus, are structurally related to AZT. AZddA and AZddG have been shown to inhibit HIV-1 replication in culture, and the 5′-triphosphate forms of these analogs inhibit the DNA polymerase activity of HIV-1 RT in cell-free assays [29]. EC50 values for the inhibition of XMRV and HIV-1 by AZddA and AZddG were comparable, although the EC50 for XMRV22Rv1+LtatSN with AZddG was fourfold greater than that of HIV-1NL4-3 (Table 1). Importantly, the concentrations of AZddA, AZddG and AZT required to inhibit XMRV infection were at least 100-fold lower than the 50% cytotoxic concentrations (CC50 values) of these analogs in HeLa-CD4 cell cultures (> 270 μM for all three inhibitors; [29]).

We also measured the anti-XMRV activity of adefovir, an acyclic nucleoside phosphonate that is used in prodrug form (adefovir dipivoxil) to treat hepatitis B virus infection. EC50 measurements for the activity of adefovir against XMRVVP62+LtatSN, XMRV22Rv1+LtatSN and HIV-1NL4-3 varied by a factor of twofold or less; these differences were not statistically significant (Table 1).

Taken together, these data show that XMRV is sensitive to AZT, AZddA, AZddG, tenofovir and adefovir at doses that are comparable to those required to inhibit HIV-1 replication. At the highest concentrations of the drugs used in our assays (10 μM for AZT, 40 μM for AZddA and AZddG and 100 μM for adefovir and tenofovir), the mean numbers of cells in the fixed and stained cultures were 80-100% of untreated controls, indicating that the EC50 values obtained for these analogs were not influenced by drug-mediated cytotoxicity.

XMRV is resistant to NNRTIs and to the pyrophosphate analog foscarnet

Nevirapine, efavirenz and other NNRTIs inhibit HIV-1 RT by binding to a small hydrophobic pocket located near the polymerase active site [30]. Although wild-type strains of HIV-1 Group M are sensitive to NNRTIs, HIV type 2 (HIV-2), simian immunodeficiency virus and many Group O isolates of HIV-1 are intrinsically resistant to this drug class. Consistent with the relatively narrow spectrum of NNRTI-mediated antiviral activity, both strains of XMRV were >18-fold and >200-fold resistant to nevirapine and efavirenz, respectively, relative to HIV-1NL4-3 (Table 1). In contrast, the pyrophosphate analog foscarnet (PFA) is active against many

| Table 1 Susceptibility of XMRV and HIV-1 to reverse transcriptase inhibitors |
|-----------------|-----------------|-----------------|
| Inhibitor class | Inhibitor       | EC50 (μM)       |
| NRTI            |                 | HIV-1NL4-3      | XMRVVP62+LtatSN | XMRV22Rv1+LtatSN |
|                 |                 |                 |                 |                 |
| AZT             | 0.10 ± 0.05     | 0.12 ± 0.03     | 0.06 ± 0.02     |
| AZddG           | 0.71 ± 0.01     | 1.1 ± 0.1       | 2.7 ± 0.7       |
| AZddA           | 2.0 ± 0.9       | 1.6 ± 0.4       | 3.2 ± 1.2       |
| tenofovir       | 3.5 ± 0.9       | 5.8 ± 3.2       | 5.3 ± 3.8       |
| adeovir         | 14 ± 2          | 9.5 ± 3.7       | 7.0 ± 0.8       |
| d4T             | 0.99 ± 0.53     | 34 ± 22         | 13 ± 1          |
| ddI             | 1.79 ± 0.04     | 43 ± 23         | 43 ± 12         |
| abacavir        | 3.6 ± 1.9       | 94 ± 54         | 66 ± 39         |
| 3TC             | 0.33 ± 0.07     | > 40 (> 100)    | > 40 (> 100)    |
| FTC             | 0.059 ± 0.041   | > 40 (> 100)    | > 40 (> 100)    |
| NNRTI           |                 |                 |                 |
| efavirenz       | 0.005 ± 0.002   | > 1 (> 200)     | > 1 (> 200)     |
| nevirapine      | 0.22 ± 0.07     | > 4 (> 18)      | > 4 (> 18)      |
| PPi, analog     | 126 ± 93        | > 400 (> 3)     | > 400 (> 3)     |

* EC50 values were measured in MAGIC-5A cells as described in Methods and are the means ± standard deviation from two or more independent experiments. Numbers in parentheses indicate the fold change in EC50 relative to HIV-1NL4-3. Values shown in bold are significantly different from the corresponding values for HIV-1NL4-3 (p < 0.05, ANOVA with Tukey’s multiple comparison test).

b NRTI, nucleoside reverse transcriptase inhibitor. NNRTI, non-nucleoside reverse transcriptase inhibitor. PPi, analog, pyrophosphate analog.
c See Abbreviations for drug names.
d XMRV-pseudotyped LtatSN virus. See text for details.
DNA viruses and retroviruses including HIV-1 and -2, Rauscher MLV, Moloney MLV, hepatitis B virus, cytomegalovirus and herpes simplex virus [31]. Despite this broad spectrum of antiviral activity, XMRVVP62+LtatSN and XMRV22Rv1+LtatSN were resistant to PFA (Table 1). Concentrations of PFA as high as 400 μM had no effect on XMRV infection; increasing the drug level to 900 μM produced visible cytotoxic effects in MAGIC-5A indicator cell cultures (data not shown).

XMRV is intrinsically resistant to PIs but is sensitive to integrase inhibitors

To identify antivirals that inhibit XMRV targets other than RT, we assessed the ability of nine different HIV-1 PIs to block the production of newly-formed, infectious XMRVVP62+LtatSN in chronically-infected HTX cultures. In these experiments, we screened each PI for anti-XMRV activity using a single drug concentration that was approximately equal to the EC95 for HIV-1NL4-3, as determined in our concurrent studies of HIV-1 and HIV-2 (range = 0.1-1 μM; see Methods section for details). As seen in our previous assays, these PI doses reduced the infectious titer of HIV-1NL4-3 in pNL4-3-transfected 293T/17 cultures by 94% or greater, relative to untreated controls (Figure 2). In contrast, each of the nine PI treatments had no detectable effect on the infectious titer of XMRVVP62+LtatSN, indicating that XMRVVP62 is intrinsically resistant to this inhibitor class. These results are consistent with a recent report showing that XMRV is relatively insensitive to PIs (EC50 values ≥34 μM) in cultures of immortalized human breast cancer cells [23].

We also examined the susceptibility of XMRV to two different inhibitors of HIV-1 integrase strand-transfer activity: raltegravir and elvitegravir. Of the 24 antiretroviral drugs tested in our analysis, raltegravir was the most potent inhibitor of XMRV infection. XMRV and HIV-1 exhibited comparable sensitivity to raltegravir, as the EC50 values for XMRVVP62+LtatSN and XMRV22Rv1+LtatSN were similar to that of HIV-1NL4-3 (Table 2). Elvitegravir also inhibited XMRV infection in our indicator cell assays, but higher doses of the drug were required to observe this activity. EC50 measurements for XMRVVP62+LtatSN and XMRV22Rv1+LtatSN were 71- and 40-fold greater for elvitegravir relative to raltegravir and 79- and 46-fold higher than the EC50 for elvitegravir-mediated inhibition of HIV-1NL4-3, respectively (Table 2). Although these data show that elvitegravir is less potent than raltegravir against XMRV, we note that elvitegravir inhibited the virus at concentrations in the nanomolar range, and thus, was comparable to AZT with respect to anti-XMRV activity (Tables 1 and 2). For both raltegravir and elvitegravir, no statistically-significant declines in mean target cell number were observed at the highest doses of drugs tested (10 μM; p > 0.05, Student’s two-sided t-test). This result agrees with previously-published CC50 values for raltegravir and elvitegravir in PBMC (> 100 μM and 40 μM, respectively; [23,32]) and excludes cytotoxicity as a potential confounder in our measurements of integrase inhibitor susceptibility.

Discussion

In this study, we used a novel marker transfer assay to directly compare the susceptibility of XMRV and HIV-1 to a panel of antiretroviral drugs in the same host cell type. Our experimental approach and findings differ from previous studies of XMRV in several important

Table 2 Susceptibility of XMRV and HIV-1 to integrase inhibitors

| Inhibitor | HIV-1NL4-3 | XMRVVP62+LtatSN | XMRV22Rv1+LtatSN |
|-----------|------------|-----------------|------------------|
| raltegravir | 3.7 ± 2.1 | 2.1 ± 1.1 (1) | 2.2 ± 1.1 (1) |
| elvitegravir | 1.9 ± 0.7 | 150 ± 115 (79) | 87 ± 29 (46) |

*EC50 values were measured in MAGIC-5A cells as described in Methods and are the means ± standard deviation from two or more independent experiments. Numbers in parentheses indicate the fold change in EC50 relative to HIV-1NL4-3. Values shown in bold are significantly different from the corresponding values for HIV-1NL4-3 (p < 0.05, ANOVA with Tukey’s multiple comparison test).

b XMRV-pseudotyped LtatSN virus. See text for details.
ways. With regard to NRTIs, the initial report by Sakuma et al. [21] suggested that XMRV is sensitive to AZT but resistant to 3TC, d4T and tenofovir. Importantly, the single dose of tenofovir used in their experiments (30 nM) was substantially lower than the EC_{50} observed in our assays (~5 μM; Table 1), leading the authors to conclude that XMRV was resistant to the drug. Our analysis shows that tenofovir is equally potent against XMRV and HIV-1 in culture (Table 1). A subsequent study by Singh et al. [23] used differing cell types to compare XMRV and HIV-1, and as a result, differences in the intrinsic NRTI susceptibilities of the two viruses could not be resolved from host cell-specific differences in NRTI activity. In fact, careful inspection of their data suggests that XMRV is relatively resistant to AZT, tenofovir and TDF (a produg of tenofovir), as the EC_{50} values for these analogs were 15-94-fold higher for XMRV compared to HIV-1. Our data are more congruent with the findings of Paprotka et al. [22], who showed that XMRV and HIV-1 are comparably sensitive to AZT and TDF in prostate cancer cells. We extend these observations by demonstrating that, in addition to AZT and tenofovir, the NRTIs AZddA, AZddG and adefovir are equally active against XMRV and HIV-1 (Table 1). Taken together, our analysis resolves disparities among earlier reports of XMRV drug susceptibility and illustrates that XMRV is sensitive to a broader range of NRTIs than was previously appreciated.

Overall, the patterns of drug susceptibility observed in our analysis of XMRV are similar to those seen in previous studies of Moloney MLV (MoMLV). MoMLV is sensitive to AZT, adefovir and tenofovir, but is relatively resistant to ddd, d4T, 3TC, abacavir and PFA [33-36]. In addition, purified MoMLV protease is highly resistant to PIs [37], whereas both raltegravir and elvitegravir have been shown to inhibit MoMLV replication in culture [38,39]. In agreement with our findings for XMRV (Table 2), MoMLV is moderately resistant to elvitegravir, as evidenced by a 7-fold greater EC_{50} for the drug relative to HIV-1 [39]. These concurrent drug sensitivity patterns are consistent with the high degree of amino acid sequence similarity shared between XMRV and MoMLV, which are 99% identical in the protease and RT polymerase domain and 90% identical in the integrase catalytic core domain (CCD).

To gain further insights into the molecular basis of antiretroviral drug resistance in XMRV, we constructed amino acid alignments of the inferred XMRV_{VP62} and HIV-1_{NL4-3} sequences for the entire protease enzyme, the portion of RT spanning the conserved polymerase motifs, and the integrase CCD (Figure 3). Within these three regions, XMRV and HIV-1 share 27-31% amino acid identity and 18-21% amino acid similarity. Importantly, the XMRV and HIV-1 sequences differ at several sites that are critical for antiretroviral drug resistance. XMRV protease contains three residues (V54, S81, and L92) that correspond to PI resistance-conferring replacements in HIV-1 (I47V, T74S, and L84I, respectively) (Figure 3A) [40]. XMRV also contains several amino acid residues in the RT polymerase domain that, in HIV-1, result in NNRTI resistance (K101P, K103H, Y181L, Y188L, and G190A) and dideoxynucleoside analog resistance (T69N, L74V, Y115F) (Figure 3B) [40,41]. These sites likely contribute to intrinsic drug resistance in XMRV. In addition, XMRV integrase contains a serine at the position corresponding to Q148 in HIV-1 (Figure 3C), which is known to be critical for integrase inhibitor resistance in HIV-1 [42]. This amino acid difference may contribute to moderate elvitegravir resistance in XMRV (Table 2).

As observed in previous studies of MoMLV RT [43,44], XMRV was highly resistant to the L-pseudosugar nucleoside analogs 3TC and FTC (Table 1). Both MoMLV and XMRV RT encode a valine at the second position of the conserved YXDD sequence of polymerase motif C, whereas the corresponding residue in HIV-1 RT is methionine 184 (Figure 3B). Although the M184V replacement confers high-level resistance to 3TC and FTC in HIV-1 [45], mutants of MoMLV that harbor the reciprocal change in the YXDD sequence (V223M) remain highly resistant to 3TC [43,44]. It is therefore likely that amino acid sites outside the YXDD sequence of RT contribute to intrinsic 3TC/FTC resistance in XMRV.

In HIV-1 RT, specific substitutions at positions 41, 67, 70, 210, 215 and 219 (commonly known as thymidine analog mutations or TAMs) confer AZT resistance by enhancing RT-catalyzed excision of AZT-5′-monophosphate from the nascent DNA strand [46]. Although the sequences of XMRV and HIV-1 differ at five of the six TAM sites in RT (Figure 3B), these residues are unlikely to influence AZT susceptibility in XMRV, as the excision activity of MoMLV RT is orders of magnitude lower than that of the HIV-1 enzyme [47]. Indeed, we observed that XMRV and HIV-1 were comparably sensitive to AZT as well as two other NRTIs containing a 5′-azido modification (AZddA and AZddG; Table 1). Based on previous studies of HIV-1 and MoMLV [29,48,49], we expect that XMRV RT can utilize the 5′-triphosphate forms of these analogs as alternative nucleotide substrates, resulting in chain termination of DNA synthesis. Additional biochemical analyses are required to characterize the nucleotide selectivity and excision activity of XMRV RT.

Two recently-published reports have shown that the integrase inhibitor raltegravir inhibits XMRV replication in culture at nanomolar concentrations of the drug [22,23]. Our results confirm these findings and demonstrate that elvitegravir is also active against XMRV,
Alignment of Pro and Pol amino acid sequences for XMRV and HIV-1

Alignments are shown for the protease, reverse transcriptase pol, and integrase catalytic core domain (CCD) sequences of XMRVVP62 and HIV-1NL4-3 ([GenBank: NC_007815.1] and [GenBank: M19921], respectively). Numbering for XMRVVP62 is based on assigned amino acid numbers for the corresponding MoMLV peptides [GenBank: AF033811]. Alignments were generated using EMBOSS [62] with the following settings: gap-open = 10, gap extend = 0.5, algorithm = needle (global), scoring matrix = BLOSUM62. Amino acid identities between XMRVVP62 and HIV-1NL4-3 are shown with yellow boxes, conserved amino acid residues (BLOSUM62 score ≥ 1) are shown with grey boxes, and alignment gaps are indicated with a dash (-). Catalytic active site residues are indicated with an asterisk (*). For RT, the initial EMBOSS alignment was manually adjusted to conform to a recent structural alignment of MoMLV and HIV-1 RTs [63]. Boundary boxes for conserved polymerase motifs A-D are shown as previously assigned [64]. Boundaries for motif F are shown as identified in alignments of viral RNA-dependent RNA polymerases [65]. The X at position five of XMRV protease indicates the location of a termination codon that, in MLV, is suppressed during translation of Gag-Pol-encoding RNA. Sites involved in antiretroviral drug resistance in HIV-1, as tabulated by the International AIDS Society-USA (for protease and RT) [40] or in the Stanford University HIV Drug Resistance Database (for integrase) [66] are indicated in bold, colored letters. The locations of primary PI, NRTI, and NNRTI resistance mutations, as well as changes associated with resistance to the integrase inhibitors raltegravir and elvitegravir, are shown in red. Sites involved in NNRTI resistance are shown in blue. Pound signs (#) indicate amino acid residues believed to be important for the positioning of strand transfer inhibitors, based on a recent structural analysis of prototype foamy virus integrase [51].

|                | XMRV              | HIV-1             |
|----------------|-------------------|-------------------|
| **Protease**   |                   |                   |
| XMRV           | **1** TLGDXGQGGQVLPFFPEKETLKVGGQPVTFLVTGAGQHSLQVLPGLDK 50 |
| HIV-1          | **1** PQILWQFPLTVTICTKGQLKEALDGTADTVLEMLNGW 43 |
| XMRV           | 51 SAVWGGATGCYKRWTDKVLATGKVTSHFLVDPDCPYSSLRLGLTLK 100 |
| HIV-1          | 44 FVKGQGGIPFVRGQYDQILEIECQGHAIGVLVGPTVNHIELMLLTQ 92 |
| XMRV           | 101 LQAQHPEGSGAQVVGPMQGQLVL 125 |
| HIV-1          | 93 FQCTLENF 99 |

|                | XMRV              | HIV-1             |
|----------------|-------------------|-------------------|
| **Reverse Transcriptase pol domain** |                   |                   |
| XMRV           | 40 LAVQAPLIELKATSTFISIKYPMQXARLHGPQHRLGDQ-IL-V 87 |
| HIV-1          | 1 PISPIETVPYLFQMGDPYKQWPLFEIKALQVICTHEKSKIKF 50 |
| XMRV           | 88 PCQSPWNTPLLKVPPGENDYRPVQDLREVNKRVED---IHTTVFNPYNL 134 |
| HIV-1          | 51 PGENDYNTFPAIKKDSTKWRKLDFRENKRQDPEVQGLIPHPAGL 100 |
| XMRV           | 135 LSGLPSHSTVTLDPLKDAFCRHELHPTSQPLFAKERDPMECLG-QL 183 |
| HIV-1          | -----QKKSSTVTLGDAFTSLDEKDFKRFYATIPSINNETPGRYQ 145 |
| XMRV           | 184 WTRLPQFNGRSTPLFLDLRARLHPICHPDQLLLQYLDLLLAATS-E 232 |
| HIV-1          | 146 RNLPLGQWRGSPQAIPQSMTTRLLEPSHRQPNIQVYQDDLLVIDELEI 195 |

|                | XMRV              | HIV-1             |
|----------------|-------------------|-------------------|
| **Integrate CCD** |                   |                   |
| XMRV           | 110 YVRQHRPGTTHWEVDFTPVEGKYLLTVDDFSGWSEAPFTKREF 159 |
| HIV-1          | 54 VDCS---PGI-WQDCDTH---LEQ-KVLILVAVHHSGLEAQVPCAET 94 |
| XMRV           | 160 KVVSKKLEDIFRECPMQVQLEHDGAFASOVQSVAKLGIDWMKLCAB 209 |
| HIV-1          | 95 QETAYFLK-LAGHRPV-KTVTDNGSNFTSTTVKACWWAGIKQEGIP 142 |
| XMRV           | 210 YPFQGSGQVEHHMRNRTIKETL 229 |
| HIV-1          | 143 YNFSQGVVESSNMELKII 162 |

Figure 3 Alignment of Pro and Pol amino acid sequences for XMRV and HIV-1. Alignments are shown for the protease (panel A), amino-terminal RT (panel B) and integrase catalytic core domain (CCD) sequences (panel C) of XMRVVP62 and HIV-1NL4-3 ([GenBank: NC_007815.1] and [GenBank: M19921], respectively). Numbering for XMRVVP62 is based on assigned amino acid numbers for the corresponding MoMLV peptides [GenBank: AF033811]. Alignments were generated using EMBOSS [62] with the following settings: gap-open = 10, gap extend = 0.5, algorithm = needle (global), scoring matrix = BLOSUM62. Amino acid identities between XMRVVP62 and HIV-1NL4-3 are shown with yellow boxes, conserved amino acid residues (BLOSUM62 score ≥ 1) are shown with grey boxes, and alignment gaps are indicated with a dash (-). Catalytic active site residues are indicated with an asterisk (*). For RT, the initial EMBOSS alignment was manually adjusted to conform to a recent structural alignment of MoMLV and HIV-1 RTs [63]. Boundary boxes for conserved polymerase motifs A-D are shown as previously assigned [64]. Boundaries for motif F are shown as identified in alignments of viral RNA-dependent RNA polymerases [65]. The X at position five of XMRV protease indicates the location of a termination codon that, in MLV, is suppressed during translation of Gag-Pol-encoding RNA. Sites involved in antiretroviral drug resistance in HIV-1, as tabulated by the International AIDS Society-USA (for protease and RT) [40] or in the Stanford University HIV Drug Resistance Database (for integrase) [66] are indicated in bold, colored letters. The locations of primary PI, NRTI, and NNRTI resistance mutations, as well as changes associated with resistance to the integrase inhibitors raltegravir and elvitegravir, are shown in red. Sites involved in NNRTI resistance are shown in blue. Pound signs (#) indicate amino acid residues believed to be important for the positioning of strand transfer inhibitors, based on a recent structural analysis of prototype foamy virus integrase [51].
although the concentrations of elvitegravir needed to inhibit XMRV infection were higher than those required for raltegravir (Table 2). A third integrase inhibitor, L-870812, has also been reported to exert moderate antiviral activity against XMRV in culture, with an EC50 32-fold greater than that of raltegravir [23]. Although raltegravir, elvitegravir and L-870812 are structurally divergent, these three inhibitors share a common pharmacophore that binds the active site metal ions essential for integrase strand transfer catalysis [50]. Recent crystallographic studies have identified three amino acid residues that are believed to influence the positioning of strand transfer inhibitors in the integrase active site [51], and based on our alignment of the CCD, these residues are conserved in the XMRV and HIV-1 integrase sequences (Figure 3C). Taken together, these data suggest that the strand transfer inhibitor-binding sites of XMRV and HIV-1 integrase share a similar overall topology despite numerous amino acid differences in the CCD.

We used two independent sources of XMRV for our studies: one derived from the infectious molecular clone VP62 [11] and the other from 22Rv1 prostate carcinoma cells [7]. Our rationale for this choice was that the VP62 clone might encode alterations that influence drug susceptibility, whereas 22Rv1 cells harbor at least 10 proviral copies of XMRV, presumably providing a more diverse sample of the virus. However, a recent analysis of XMRV sequences from 22Rv1 cells revealed that the proviruses are nearly identical to each other and to the VP62 molecular clone [22]. There are only two nucleotide differences between the consensus XMRV22Rv1 and XMRVVP62 sequences ([GenBank: FN6900043] and [GenBank: EF185282], respectively); these result in single amino acid changes in Gag and Env, whereas the Pro and Pol proteins are identical. Thus, the key proteins targeted by the antiretroviral drugs tested in our study are identical in XMRV22Rv1 and XMRVVP62. This identity is reflected in the similar EC50 values obtained for these two viruses (Tables 1 and 2). Strikingly, all six of the full-length XMRV sequences currently available in GenBank show a high degree of nucleotide identity (Figure 4). Although the lack of variation reported in XMRV is difficult to reconcile with the known mutation rates of MoMLV and other retroviruses, collectively, these sequencing results suggest that the drugs that are active against XMRV22Rv1 and XMRVVP62 should be similarly active against other XMRV strains.

**Conclusions**

Our analysis demonstrates that XMRV is sensitive to a broader range of NRTIs than was previously appreciated; these include analogs that are used in the clinical treatment of HIV-1 infection (AZT and tenofovir) as well as other structurally-related NRTIs (AZddA, AZddG and adefovir). We observed a distinct pattern of NRTI sensitivity in XMRV that correlates with the structure of the pseudosugar moiety; while XMRV is sensitive to 3′-azido nucleoside analogs and acyclic nucleoside phosphonates, the virus is moderately resistant to dideoxynucleosides and highly resistant to L-form thiacytidine NRTIs. Importantly, this pattern suggests that other 3′-azido or acyclic nucleoside analogs might also exhibit anti-XMRV activity. In addition, our data show that elvitegravir blocks XMRV infection with a degree of potency similar to that of AZT. This finding expands the number of integrase inhibitors with known activity against XMRV *in vitro*. 

**Figure 4 Phylogenetic analysis of XMRV.** All full-length XMRV sequences available in GenBank (accessed on April 28, 2010) were aligned using ClustalW. Unrooted (panel A) and rooted (panel B) phylogenetic trees were generated using the neighbor-joining algorithm of MEGA 4.0 [67] with default settings. Scale bars indicate evolutionary distance in base substitutions per site (i.e., the distance shown in panel A equals 2 substitutions per 10,000 bases). Note that after the original sequencing of XMRV strains VP62, VP42 and VP35 [3], strain VP62 was resequenced (“VP62 corrected”; [11]). The resulting sequence reveals a closer similarity between VP62 and other XMRV strains and suggests that the branch lengths of VP35 and VP42 are also likely overestimated due to PCR or sequencing errors. mChrom13 indicates an endogenous MLV sequence located on *Mus musculus* chromosome 13 [GenBank: CT03065S7] and is the most closely related non-XMRV sequence found by BLAST search of GenBank using the XMRV22Rv1 sequence. DG-75 indicates DG-75 MLV [GenBank: AF221065].
While our use of the same target cell type for XMRV and HIV-1 provides an important reference point for characterizing XMRV drug susceptibility, we note that the two viruses utilize different receptors for entry and are therefore likely to infect differing host cell types in vivo. Ultimately, the clinical utility of antiretrovirals for XMRV will depend on drug distribution and metabolism at anatomic sites of XMRV replication, the degree to which antiretrovirals reduce XMRV viral load, and whether reductions in viral load slow pathogenesis. In the event that XMRV is shown to be the causative agent of human disease, our data identify candidate drugs for clinical studies of antiretroviral therapy in XMRV-infected patients.

Methods

Inhibitors

AZT (generic name: zidovudine; 3′-azido-3′-deoxythymidine), ddI (didanosine; 2′,3′-dideoxyinosine), D4T ( stavudine; 2′,3′-didehydro-3′-deoxythymidine) and PFA (foscarne; phosphonoformic acid) were obtained commercially (Sigma-Aldrich), as were adefovir ([3′,4′,5′]-azido-2-cyclopentene-1-methanol) (Moravek Biochemicals), tenofovir ([3′,4′,5′]-phosphonylethoxyparyl)adenine) and abacavir ([15S,4R]-4′-[2-amino-6-(cyclopenta)-9H-purin-9-yl]-2-cyclopentene-1-methanol) (Moravek Biochemicals). AZddA (3′-azido-2′,3′-dideoxyadenosine) and AZddG (3′-azido-2′,3′-dideoxyguanosine) (Berray and Associates), and elvitegravir (Selleck Chemicals). Nevirapine and efavirenz were a gift from Koronis Pharmaceuticals (Seattle, Washington). 3TC (lamivudine; (-)-β-L-2′,3′-dideoxy-3′-thiacytidine) and FTC (emtricitabine; (-)-β-L-2′,3′-dideoxy-5-fluoro-3′-thiacytidine) were kindly provided by Raymond Schinazi (Emory University) or were purchased from Moravek. All HIV-1 PIs used in this study, as well as the integrase inhibitor raltegravir, were obtained from the National Institutes of Health AIDS Reference Reagent Program.

Cell culture and virus production

HTX cells are a pseudoploid subclone of HT-1080 human fibrosarcoma cells [52]. The LtatSN vector was created by inserting the tat coding region of HIV strain SF2 into the retroviral expression vector LXSN [53]. HTX/LtatSN cells were generated by infecting HTX cells with helper-virus free LtatSN virus that was produced in PA317 amphotropic packaging cells [54] and then treating the cells with G418 (geneticin) to select for the presence of the vector. 22Rv1 cells [27] and 293T/17 cells [55] were obtained from the American Type Culture Collection. MAGIC-5A indicator cells (CD4+/CCR5+ HeLa cells that express β-galactosidase (β-gal) under the control of an HIV-1 LTR promoter) [26] were a kind gift from Dr. Michael Emerman (Fred Hutchinson Cancer Research Center). Cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum.

XMRV-pseudotyped LtatSN virus (XMRV+LtatSN) was generated by infecting HTX/LtatSN cells with virus produced from the VP62 molecular clone of XMRV (a kind gift from Robert Silverman, Cleveland Clinic) [11] or with virus harvested from XMRV-infected 22Rv1 cells [7]. HIV-1NL4-3 was produced using the full-length pNL4-3 HIV-1 plasmid molecular clone [56]. Plasmid DNA was isolated from pNL4-3-transformed E. coli JM109 using an Endo-Free™ maxiprep kit (Qiagen) and introduced into cultured 293T/17 cells via chloroquine-mediated transfection as previously described [57]. XMRVVP62+LtatSN, XMRV22Rv1+LtatSN and HIV-1NL4-3 stocks were harvested from confluent monolayers of producer cells, passed through 0.45-micron filters (XMRV+LtatSN) or centrifuged at 500 × g for 10 min at room temperature (HIV-1 NL4-3 ) to remove host cells, and frozen in multiple aliquots at -70°C. Titers of the resultant stocks were 7.3 × 10^5, 1.2 × 10^6, and 3.0 × 10^6 MAGIC-5A focus forming units (FFU)/ml for XMRVVP62+LtatSN, XMRV22Rv1+LtatSN and HIV-1NL4-3, respectively.

Drug Susceptibility Assays-RT and Integrase Inhibitors

To compare the susceptibilities of XMRV and HIV-1 to NRTIs, NNRTIs and PFA, MAGIC-5A cells were seeded into 48-well plates at 1.5 × 10^4 cells/well. After 20-22 h of incubation, the cultures were dosed with varying drug concentrations and returned to the incubator for an additional 2.5 h. Immediately before infection, virus stocks were diluted to 3,000 FFU/ml in complete DMEM supplemented with 20 μg/ml diethylaminoethel (DEAE) dextran. Supernatants from the drug-treated MAGIC-5A cultures were then aspirated and replaced with 100 μl of each diluted virus stock/well. To maintain drug pressure, a second dose of inhibitor was added to the inocula (at the same concentration as the first dose), and the plates were returned to the incubator for 2.5 h. After this time, an additional 300 μl of complete DMEM was added, a third dose of drug was added, and incubation was continued for 40 h. Individual dose-response experiments for each virus strain involved 2-3 solvent-only control cultures plus 2-3 cultures for each of seven different drug concentrations.

To score β-gal-positive (β-gal+) foci, 100 μl of fixative solution [1% formaldehyde, 0.2% glutaraldehyde in 1× phosphate-buffered saline (PBS)] was added to each culture well, and the plates were incubated at 37°C for 10 min. After washing the fixed monolayers twice with 100 μl of PBS, 100 μl of staining solution [4 mM
potassium ferrocyanide, 4 mM potassium ferricyanide, 2 mM MgCl₂ and 0.4 mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) in PBS] was added to each well, and the plates were placed in the incubator for 1 h. The cultures were then aspirated to remove the X-gal staining solution, rinsed with 100 μl of PBS per well, aspirated again and stored in 200 μl of PBS per well. Foci (individual β-gal⁺ cells plus groups of 2-8 contiguous β-gal⁺ cells) were counted using a CTL Immunospot Analyzer (Cellular Technology Ltd.) or were manually counted by light microscopy. Untreated control cultures typically contained 200-500 foci per well.

To quantify viral susceptibility to integrate inhibitors, we adopted our MAGIC-5A-based assay to a 96-well format and used an expanded range of drug concentrations. These changes were necessitated by the shallow slopes observed in dose-response plots with raltegravir and elvitegravir relative to inhibitors from other drug classes [58]. Culture conditions and times of drug addition were identical to those used for the RT inhibitor assays, except that each culture well was seeded with 5 × 10⁵ MAGIC-5A cells in 100 μl of medium, was infected with 200 FFU of virus in 50 μl of dextran-containing medium, and received an additional 150 μl of complete medium following the 2.5 h incubation period. Fixing and X-gal-staining steps were performed with one half of the volumes of solutions used in RT inhibitor assays, and β-gal⁺ foci were counted using the CTL Immunospot Analyzer.

Drug concentrations that inhibited focus formation by 50% (EC₅₀ values) were calculated from dose-response plots by sigmoidal regression analysis (GraphPad Software). EC₅₀ measurements for HIV-1NL4-3 were comparable to the values obtained in other single-cycle drug sensitivity assays [26,59,60]. Potential drug-mediated cytotoxicity was assessed by comparing the number of cells in untreated control cultures to those in cultures that received the maximal dosage of drug used in our assays. Fixed cells were stained by exposing the MAGIC-5A monolayers to 10 μg/ml ethidium bromide in PBS for 5 min, then de-staining for 5 min in deionized water. Cell nuclei were visualized by fluorescence microscopy using a Texas red filter set (560 nm excitation, 645 nm emission). Images were acquired from 3-4 culture wells for each drug treatment and corresponding no-drug controls, and nuclei were enumerated using ImageJ software [61].

Drug Susceptibility Assays-Protease Inhibitors
To measure PI susceptibility, cultured cells that were producing either HIV-1 or XMRV were treated with varying doses of PIs, and the numbers of infectious virus particles released by each drug-treated or no-drug control culture were quantified in MAGIC-5A indicator cells. For HIV-1NL4-3, 293T/17 cells grown in 75 cm² flasks were digested with trypsin, seeded into 48-well plates at 6 × 10⁵ cells/well, and placed in an incubator. The following day (20-24 h), CaPO₄-DNA co-precipitates were prepared by mixing 5 μg of HIV-1NL4-3 plasmid DNA with 900 μl of 0.2 M CaCl₂, adding the solution dropwise with mixing into 900 μl of 2× Hepes-buffered saline, and then incubating the suspension at room temperature for 10 min. During this time, chloroquine was added to each 293T/17 culture well to a final concentration of 50 μM. Co-precipitate suspensions were then mixed by pipetting and added directly to the chloroquine-treated cultures (20 μl/well), and the plates were placed in the incubator for 10-12 h. Following this incubation period, the supernatants were aspirated and replaced with 400 μl of fresh medium per well, and PIs were added to the culture wells. The plates were then returned to the incubator for 30-35 h. Supernatants (20 μl) from the transfected 293T/17 cultures were removed without disturbing the cell monolayer and diluted 1:10, 1:100 and 1:1,000 in complete medium supplemented with 20 μg/ml DEAE dextran. Infectious titers in the diluted supernatants were measured in MAGIC-5A cells as described above, except that inhibitors were omitted from this phase of the assay.

For PI susceptibility assays with XMRV, HTX/LtatSN cells that were infected with XMRVVP62 were trypsinized, rinsed twice with 1× PBS, resuspended in complete medium and seeded into 48-well plates at approximately 5 × 10⁴ cells/well. The cultures were then immediately treated with PIs as described above for HIV-1NL4-3. Following a 40-h incubation period, 180 μl of culture supernatant was harvested from each well, and DEAE-dextran was added to the samples to a final concentration of 20 μg/ml. The supernatants were diluted 1:4 and 1:16 in medium containing 20 μg/ml DEAE dextran, and 100 μl each of the undiluted, 1:4- and 1:16-diluted samples were transferred to MAGIC-5A cultures for FFU determination as described above.

Abbreviations
XMRV: xenotropic murine leukemia virus-related virus; HIV-1: human immunodeficiency virus type 1; RT: reverse transcriptase; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; AZT: generic name-zidovudine, 3′-azido-3′-deoxythymidine; 2′,3′-dideoxy-3′-thiacytidine; PFA: foscarnet, phosphonoformic acid; IDV: indinavir; LPV: lopinavir; Ritonavir; DRV: darunavir; APV: amprenavir; ATV: atazanavir; NFV: nelfinavir; RTV: ritonavir; EFV: efavirenz; SQV: saquinavir; IDV: IND; 3TC: emtricitabine; DDI: didanosine; LPV: LPV; 3TC: 3′-azido-3′-thiacytidine; RTV: ritonavir; AZT: 3′-azido-3′-deoxythymidine; IDV: indinavir; LPV: lopinavir; 3TC: emtricitabine; EFV: efavirenz; RTV: ritonavir; APV: amprenavir; ATV: atazanavir; NFV: nelfinavir; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; AZT: generic name-zidovudine, 3′-azido-3′-deoxythymidine; 2′,3′-dideoxy-3′-thiacytidine; PFA: foscarnet, phosphonoformic acid; IDV: indinavir; LPV: lopinavir; 3TC: 3′-azido-3′-thiacytidine; RTV: ritonavir; APV: amprenavir; TPV: tipranavir; DRV: darunavir; FFU: focus-forming units; EC₅₀: the concentration of drug required to inhibit infection by 50%;
ANOVA: analysis of variance; FDA: United States Food and Drug Administration.

Acknowledgements
We thank Robert Silverman (Cleveland Clinic) for providing the plasmid encoding the full-length infectious clone of XMRV_prop2 (pVP62). This work was supported by a New Investigator Award to RAS from the University of Washington Center for AIDS Research (U54-CFAR, P30 AI027757), the UW-CFAR Computational Core, and Public Health Service grants R01 AI060466 to GSG and P30 DK56666 to ADM. We thank Jim Mullins (UW) for additional support (R37 AI47736) and both Jim Mullins and John Mittler (UW) for helpful discussions and critical review of the manuscript.

Author details
1Department of Pathology, University of Washington, Seattle WA, USA.
2Department of Medicine, University of Washington, Seattle WA, USA.
3Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle WA, USA.

Authors’ contributions
RAS contributed to the experimental design, prepared essential reagents, acquired and analyzed the drug susceptibility data, and drafted the manuscript. ADM contributed to the experimental design, prepared essential reagents, performed the phylogenetic analysis of XMRV sequences, assisted in data acquisition and interpretation, and helped prepare the manuscript. GSG performed amino acid alignments of XMRV and HIV-1 sequences, assisted with data interpretation, contributed to the phylogenetic analysis of XMRV sequences, and helped prepare the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 1 July 2010 Accepted: 31 August 2010
Published: 31 August 2010

References
1. Coffin JM, Hughes SH, Varmus HE: Retroviruses Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press 1997.
2. Bilkstad V, Benachenhou F, Sperber GO, Blomberg J: Evolution of human endogenous retroviral sequences: a conceptual account. Cell Mol Life Sci 2008, 65:3348-3365.
3. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Smith

4. Blikstad V, Benachenhou F, Sperber GO, Blomberg J: Evolution of human endogenous retroviral sequences: a conceptual account. Cell Mol Life Sci 2008, 65:3348-3365.
5. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, Delfsi J: Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006, 2:e25.
6. Fischer N, Hellwinkel D, Schulz C, Chun FK, Huland H, Aepfelbacher M, Schlomm T: Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol 2008, 43:277-283.
7. Schläber R, Cho DJ, Brown KR, Thaker HM, Singh JR: XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci USA 2009, 106:16351-16356.
8. Arnold RS, Makeeva NV, Osunkoya AO, Suppiah S, Scott TA, Johnson NA, Bhosle SM, Lottra D, Hunter E, Marshall FF, Ly H, Molinano RJ, Blackwell JL, Petros JA: XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. J Urol 2010, 75:755-761.
9. Knouf EC, Metzger MJ, Mitchell PS, Arroyo JD, Chevillet JR, Tewari M, Miller AD: Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus related virus) from 22Rv1 prostate carcinoma cells. J Virol 2009, 83:7353-7356.
10. Hong S, Klein EA, Das Gupta J, Hanke K, Weight CJ, Nguyen C, Gaughan C, Kim KA, Bannert N, Kirchoff F, Munz J, Silverman RH: Fibrils of prostaglandin acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J Virol 2009, 83:7695-7703.
11. Rodriguez JJ, Goff SP: Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells. J Virol 2010, 84:2556-2562.
12. Stieler K, Schulz C, Lavanya M, Aepfelbacher M, Stocking C, Fischer N: Host range and cellular tropism of the human exogenous gammaretrovirus XMRV. Virology 2010, 399:23-30.
13. Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Garanem D, Dersi LL, Chow SA, Silverman RH: An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci USA 2007, 104:1655-1660.
14. Groot HC, Yap MW, Galao RP, Neil SJ, Bishop KN: Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci USA 2010, 107:5166-5171.
15. Metzger MJ, Holguin CJ, Mendoza R, Miller AD: The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells. J Virol 2010, 84:1874-1880.
16. Kim S, Kim N, Dong B, Boren D, Lee SA, Das Gupta J, Gaughan C, Klein EA, Lee C, Silverman RH, Chow SA: Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol 2008, 82:9964-9977.
17. Lombardi VC, Ruscetti FW, Das Gupta J, Plof MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrosov-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA: Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome. Science 2009, 326:585-589.
18. Groot HC, Bouchert JC, Makinson K, Randel F, Baptista S, Hagan S, Gow JW, Matthews FM, Breuner J, Kerr JR, Stope JK, Bishop KN: Absence of xenotropic murine leukemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010, 7:10.
19. Hohne O, Krause H, Barbarotto P, Neiderstadt T, Beimforde N, Denner J, Miller K, Kurth R, Bannert N: Lack of evidence for xenotropic murine leukemia virus-related (XMRV) in German prostate cancer patients. Retrovirology 2009, 6:92.
20. Erkoven O, Kaye S, McClure MO, Weber J, Willis G, Collier D, Wessely S, Cleare A: Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One 2010, 5:e8519.
21. van Kuppeveld FJ, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJ, Swaingt CM, Bleijenberg G, Netea MG, Galama JM, van der Meer JW: Prevalence of xenotropic murine leukemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ 2010, 340:c1018.
22. D’Arcy F, Foley R, Perry A, Marigond L, Lawler M, Gaffney E, Watson RGW, Fitzpatrick JM, Lynch TH: No evidence of XMRV in Irish prostate cancer patients with the R462Q mutation. European Urology Supplements 2008, 7:271.
23. Sakuma R, Sakuma T, Ohmine S, Silverman RH, Ikeda Y: Xenotropic murine leukemia virus-related virus is susceptible to AZT. J Virol 2010, 84:5719-5729.
24. Singh IR, Grozynski JE, Drobysheva D, Bassit L, Schinazi RF: Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1999, 34:436-441.
25. Miller AD, Bonham L, Alfano J, Kem HP, Reynolds T, Wolgamot G: A novel murine retrovirus identified during testing for helper virus in human gene transfer trials. J Virol 1996, 70:1804-1809.
26. Hachiya A, Azawa-Matsuoka S, Tanaka M, Takahashi Y, Ida S, Gatanaga H, Hirabayashi Y, Koijma A, Tatsumi M, Oka S: Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4+ cell clone 1-10 (MAGIC-5). Antimicrob Agents Chemother 2001, 45:495-501.
27. Iwasaki F, Uchida F: Gag 72-kDa polypeptide: a novel cellular protein in human immunodeficiency virus type 1 particles. Proc Natl Acad Sci USA 1999, 96:1385-1390.
28. Fitzpatrick JM, Lynch TH: Prevalence of xenotropic murine leukemia virus-related virus in German prostate cancer patients. Retrovirology 2010, 7:72.
29. Larder BA, Cheebro B, Richman DD: Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1999, 34:436-441.
30. Miller AD, Bonham L, Alfano J, Kem HP, Reynolds T, Wolgamot G: A novel murine retrovirus identified during testing for helper virus in human gene transfer trials. J Virol 1996, 70:1804-1809.
31. Hachiya A, Aizawa-Matsuoka S, Tanaka M, Takahashi Y, Ida S, Gatanaga H, Hirabayashi Y, Koijma A, Tatsumi M, Oka S: Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4+ cell clone 1-10 (MAGIC-5). Antimicrob Agents Chemother 2001, 45:495-501.
32. Iwasaki F, Uchida F: Gag 72-kDa polypeptide: a novel cellular protein in human immunodeficiency virus type 1 particles. Proc Natl Acad Sci USA 1999, 96:1385-1390.
29. Sluis-Cremer N, Koontz D, Bassit I, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW. Anti-human immunodeficiency virus activity, cross-resistance, cytoxicity, and intracellular pharmacology of the 3′-azido-3′-dideoxycytidine nucleosides. Antimicrob Agents Chemother 1999, 43:3715-3719.

30. Ren J, Stammers DK. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res 2008, 134:157-170.

31. Oberq B. Antiviral effects of phosphonoformate (PFA, foscamet sodium). Pharmacol Ther 1989, 40:213-285.

32. Jones GS, Yu F, Zeynaladizadeh A, Hesselslager J, Chen X, Chen J, Jin H, Kim CU, Wright M, Gelezunas R, Tsang M. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 2009, 53:1184-1203.

33. Stier PK, Nelson CJ, Mellors JW. Use of recombinant retroviruses to characterize the activity of antiretroviral compounds. J Virol 1991, 65:6339-6342.

34. Sunuga Y, Makino M, Okada Y, Tanaka H, De Clercq E, Baba M. Prevention of murine AIDS development by (RL-9-(2-phosphonomethoxymethyl)adenine. J Acquir Immune Defic Synd Hum Retrov 1998, 18:316-322.

35. Powell SK, Artlip M, Kalosio M, Bransko S, Lyons R, McGarvey GJ, Otto E. Efficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells. J Virol 1999, 73:8813-8816.

36. Rosenblum LL, Patton G, Grigg AR, Frater AJ, Cain D, Erlewine O, Hill CL, Clarke JR, McClure MO. Differential susceptibility of retroviruses to nucleoside analogues. Antivir Chem Chemother 2001, 12:91-97.

37. Feher A, Boross P, Sperka T, Miklossy G, Kadas J, Bagossi P, Oroszlan S. Purifying selection masks the susceptibility of the human retrovirus to antiretroviral agents. J Virol 1987, 62:265-270.

38. Beck-Engeser GB, Eilat D, Harrer T, Jack HM, Wabl M. In vitro activity of structurally diverse nucleoside analogues against human immunodeficiency virus type 1. J Gen Virol 2006, 87:1321-1330.

39. Beck-Engeser GB, Eilat D, Harrer T, Jack HM, Wabl M. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. Nat Med 2005, 11:35-43.

40. Johnson VA, Brun-Vezinet F, Cloret B, Gunthard HF, Kurtzkes DR, Pillay D, Schapiro JM. Information on nucleoside. J Virol 2005, 82:674-774.

41. Johnson VA, Brun-Vezinet F, Cloret B, Gunthard HF, Kurtzkes DR, Pillay D, Schapiro JM. Information on nucleoside. J Virol 2005, 82:674-774.

42. Mouscadet JF, Delpelet K, Asselin L, Tchertanov L. Resistance to HIV-1 integrase inhibitors: A structural perspective. Drug Resist Update 2010.

43. Hanks EC, Svorayovska ES, Freed EO, Pathak VK. Wild-type and YMDD mutant murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphates (3TCTP) in vitro. J Virol 2001, 75:6321-6328.

44. Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, III, Eilat D, Harrer T, Jack HM, Wabl M. Anti-human immunodeficiency virus reverse transcriptase viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1999, 43:675-681.

45. Meyer PR, Matsura SE, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999, 4:35-43.

46. Meyer PR, Matsura SE, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999, 4:35-43.

47. Meyer PR, Matsura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1996, 93:13471-13476.

48. St Clair MH, Richards CA, Specter T, Weinhold KJ, Miller WH, Langlois AJ, Furman PA. 3′-Azido-3′-dideoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987, 31:1972-1977.

49. Huang F, Farquhar D, Plunkett W. Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 1990, 265:11914-11918.

50. Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: Inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 2004, 39:377-399.

51. Hare S, Gupta SS, Valskow E, Engelman A, Cherepanov P. Retroviral integrase and inhibition of DNA strand transfer. Nature 2010, 464:232-236.

52. Batzfeld J, Nelson-Rees WA, Toth EM, Arinstein P, Gardner MB. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 1974, 33:1027-1033.

53. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989, 7:980-982, 994-996, 989-990.

54. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986, 6:2895-2902.

55. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993, 90:8392-8396.

56. Adachi A, Gendelman HE, Koening S, Folks T, Willey R, Rabson A, Martin MA. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1989, 63:284-291.

57. Smith RA, Anderson DJ, Preston BD. Purifying selection masks the mutational flexibility of HIV-1 reverse transcriptase. J Biol Chem 2004, 279:26726-26734.

58. Shen L, Petersson S, Sedaghat AR, McMahan MA, Callender M, Zhang H, Zhou Y, Pitt E, Anderson KS, Acosta EP, Silicano RJ. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008, 14:762-766.

59. Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW. In vitro activity of structurally diverse nucleoside analogues against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 2005, 49:1139-1144.

60. Mouscadet JF, Cloret B, Gunthard HF, Kurtzkes DR, Pillay D, Schapiro JM. Information on nucleoside. J Virol 2005, 82:674-774.

61. Image J Software. [http://rsb.info.nih.gov/ij].

62. EMBOSs Pairwise Alignment Algorithms. [http://www.ebi.ac.uk/Tools/emboss/align].

63. Cote ML, Roth MJ. Murine leukemia virus reverse transcriptase: structural comparison with HIV-1 reverse transcriptase. Virus Res 2008, 134:186-202.

64. Poch O, Sauvaget I, Delarue M, Tordo N. Evolutionary origins and functional genomics of the RNA-dependent RNA polymerases. EMBO J 1989, 8:3867-3874.

65. Brunetti A. A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases. Nucleic Acids Res 2003, 31:1821-1829.

66. Stanford University HIV Drug Resistance Database. [http://hivdb.stanford.edu/cgi-bin/NHarresNote.cgi].

67. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:1596-1599.

doi:10.1186/1742-4690-7-70
Cite this article as: Smith et al: Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. Retrovirology 2010 7:70.